In the NSCLC cancer patients from the non-curative cohort where the data were available, the baseline value of hPG80 was not significantly different according to the smoking status (active, n = 20; former, n = 22; never, n = 5, P = 0.83), or the molecular status regarding TP53, K-RAS, or B-RAF mutations in the NSCLC cancer patients on tumor tissue or circulating tumor DNA (Suppl Tables 1, and Suppl Figs. 12 and 13). This evidence concerns the gene KRAS and neoplasm.